Gl
Gloria Bio
Suzhou CNFounded 2018100 employees
Private CapbiotechPrivateOncology
Platform: GR1801 CD73
Market Cap
N/A
All Drugs
4
Clinical Trials
6
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Mirirasimod | GLO-3846 | NDA/BLA | 1 | PLK4 | PNHPV | ||
| Adagraderotide | GLO-2184 | Phase 1/2 | 1 | JAK2 | HSIgAN | ||
| GLO-9650 | GLO-9650 | Phase 2 | 2 | RET | DLBCLRCC | ||
| GLO-6047 | GLO-6047 | Preclinical | 2 | CD47 | PsoriasisFSGS |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (7)